Again the similarity to ASTM stands out. ASTM was just 29 Million OS prior to their PP in December but still only 39 Million now after raising $22.5 Million cash.
Both seem to be on track to do very well this year and it would probably wise to split my money between the two. It will be interesting to see how each trades tomorrow in respect to how it traded today.
ACAD traded 80% of it's volume in the first 2 hours today with no real follow through volume wise or price wise, although still a very respectable close. Also down slightly after hours.
ASTM just sort of grinded it's way up on fairly steady volume and actually had good volume into the close and closed just shy of the highs and up a tad after hours.
I try not to read to much into that stuff though with manipulation being rampant in all markets. Still nice to keep an eye on it though.
Go ACAD !!
(might want to take a peak at COCO as well)
Recent ACAD News
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 11/15/2024 09:05:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 11:48:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 09:14:26 PM
- Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview • Business Wire • 11/06/2024 09:05:00 PM
- Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million • Business Wire • 11/05/2024 09:05:00 PM
- Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 • Business Wire • 10/17/2024 10:41:00 PM
- Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome • Business Wire • 10/16/2024 08:07:00 PM
- Acadia Pharmaceuticals annonce l’approbation de DAYBUE™ (trofinétide) par Santé Canada pour le traitement du syndrome de Rett • Business Wire • 10/16/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2024 10:05:05 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 10/08/2024 08:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/26/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 10:53:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 10:46:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 09/23/2024 09:14:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:34:29 PM
- Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals • Business Wire • 09/23/2024 08:15:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 08/28/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:43:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:40:42 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:39:26 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:37:56 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:35:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:33:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:31:27 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM